A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003
A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)
Sponsor: Amgen
A observational or N/A phase clinical study on Pancreatic Cancer, this trial is ongoing. The trial is conducted by Amgen and has accumulated 6 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Approved For Marketing NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- CONKO-Studiengruppe
- Sanofi
- medac GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.